Neuland Laboratories Profile
Key Indicators
- Authorised Capital ₹ 44.00 Cr
- Paid Up Capital ₹ 12.83 Cr
- Company Age 41 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 585.57 Cr
- Satisfied Charges ₹ 2,004.23 Cr
- Revenue Growth 26.00%
- Profit Growth 156.75%
- Ebitda 90.80%
- Net Worth 18.29%
- Total Assets 14.27%
About Neuland Laboratories
Neuland Laboratories Ltd. (NLL) is a leading Public Limited Indian Non-Government Company incorporated in India on 07 January 1984 and has a history of 41 years and one month. Its registered office is in Hyderabad, Telangana, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 524558 and on the National Stock Exchange(NSE) under NEULANDLAB.
The Corporate was formerly known as Neuland Laboratories Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 44.00 Cr and a paid-up capital of Rs 12.83 Cr.
The company currently has active open charges totaling ₹585.57 Cr. The company has closed loans amounting to ₹2,004.23 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Neuland Laboratories Ltd. India are Abhijit Majumdar as CFO and Sarada Bhamidipati as Company Secretary. Prasad Menon, Homi Khusrokhan, Ramamohan Rao, and Seven other members serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
L85195TG1984PLC004393
- Company No.
004393
- Stock Symbol
BSE : 524558 NSE : NEULANDLAB
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
07 Jan 1984
- Date of AGM
27 Jul 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Listed
- ROC Code
Roc Hyderabad
Industry
What products or services does Neuland Laboratories Ltd. offer?
Neuland Laboratories Ltd. offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Anti Infective API, Dietary Supplements, Peptides.
Who are the key members and board of directors at Neuland Laboratories?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Abhijit Majumdar | CFO | 23-Nov-2022 | Current |
| Sarada Bhamidipati | Company Secretary | 03-Jan-2012 | Current |
Board Members (10)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sugata Sircar  | Director | 27-Jun-2023 | Current |
| Saharsh Davuluri | Whole-Time Director | 01-Jun-2009 | Current |
| Pallavi Bakhru | Director | 27-Jun-2023 | Current |
| Bharati Rao | Director | 09-May-2014 | Current |
| Prasad Menon | Director | 31-Oct-2022 | Current |
| Homi Khusrokhan | Director | 12-Feb-2019 | Current |
Financial Performance of Neuland Laboratories.
Neuland Laboratories Ltd., for the financial year ended 2023, experienced significant growth in revenue, with a 26% increase. The company also saw a substantial improvement in profitability, with a 156.75% increase in profit. The company's net worth Soared by an impressive increase of 18.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neuland Laboratories?
In 2023, Neuland Laboratories had a promoter holding of 36.14% and a public holding of 63.86%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Data Patterns (India) LimitedPrasad Menon is a mutual person
Ypo South Asia ChapterSucheth Davuluri is a mutual person
Azure Power India Private LimitedSugata Sircar is a mutual person
Chemplast Sanmar LimitedPrasad Menon is a mutual person
Hindustan Zinc LimitedPallavi Bakhru is a mutual person
Suprajit Engineering LimitedBharati Rao is a mutual person
Charges (Loans)
₹585.57 Cr
₹2,004.23 Cr
Charges Breakdown by Lending Institutions
- Sbicap Trustee Company Limited : 585.15 Cr
- Axis Bank Limited : 0.42 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Jul 2022 | Sbicap Trustee Company Limited | ₹585.15 Cr | Open |
| 22 Jul 2020 | Axis Bank Limited | ₹4.24 M | Open |
| 24 Sep 2021 | Others | ₹75.00 Cr | Satisfied |
| 29 Aug 2020 | Others | ₹18.75 Cr | Satisfied |
| 21 Jul 2020 | Hdfc Bank Limited | ₹35.00 Cr | Satisfied |
How Many Employees Work at Neuland Laboratories?
Neuland Laboratories has a workforce of 1860 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neuland Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neuland Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
